2 results
Approved WMORecruiting
The primary objective is to identify which coagulation factors are associated with unsuccessful reversal of VKA activity. Secondary objectives include the assessment of the number of patients reaching normalized INR (i.e. <1.8) and the number…
Approved WMORecruiting
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…